{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:59:43Z","timestamp":1783666783985,"version":"3.55.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":110,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA124435"],"award-info":[{"award-number":["P30CA124435"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101227","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:33:55Z","timestamp":1776872035000},"page":"101227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status"],"prefix":"10.1016","volume":"47","author":[{"given":"Ziheng","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline V.","family":"Aredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe C.","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel J.","family":"Myall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohana","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavitha J.","family":"Ramchandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel W.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ctarc.2026.101227_bib0001","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cancergen.2016.03.001","article-title":"The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma","volume":"209","author":"Biernacka","year":"2016","journal-title":"Cancer Genet."},{"key":"10.1016\/j.ctarc.2026.101227_bib0002","first-page":"1","article-title":"Overcoming KRAS-Mutant Lung Cancer","volume":"42","author":"Luo","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101227_bib0003","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation","volume":"387","author":"Janne","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.ctarc.2026.101227_bib0004","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101227_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107960","article-title":"Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC)","volume":"197","author":"Johnson","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101227_bib0006","first-page":"187","article-title":"Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program","author":"Passiglia","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101227_bib0007","first-page":"201","article-title":"Sotorasib in G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany","author":"Stratmann","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101227_bib0008","first-page":"36","article-title":"Real-world comparative effectiveness of sotorasib versus docetaxel monotherapy in second-line and beyond for advanced or metastatic non-small cell lung cancer (NSCLC): A national database analysis from England","author":"Summers","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101227_bib0009","first-page":"219","article-title":"Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study","author":"Wislez","year":"2025","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101227_bib0010","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","article-title":"Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC","volume":"13","author":"Negrao","year":"2023","journal-title":"Cancer Discov."},{"issue":"6664","key":"10.1016\/j.ctarc.2026.101227_bib0011","doi-asserted-by":"crossref","first-page":"eadg7492","DOI":"10.1126\/science.adg7492","article-title":"Accurate proteome-wide missense variant effect prediction with AlphaMissense","volume":"381","author":"Cheng","year":"2023","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101227_bib0012","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2012.08.024","article-title":"Genomic landscape of non-small cell lung cancer in smokers and never-smokers","volume":"150","author":"Govindan","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ctarc.2026.101227_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107361","article-title":"Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-)mutations in non-small cell lung cancer with a special focus on KRAS G12C","volume":"184","author":"Boeschen","year":"2023","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101227_bib0014","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12885-023-10778-6","article-title":"Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and\/or KEAP1 mutations in a real-world setting","volume":"23","author":"Julian","year":"2023","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101227_bib0015","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished efficacy of programmed death-(ligand)1 inhibition in stk11- and keap1-mutant lung adenocarcinoma is affected by kras mutation status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101227_bib0016","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1007\/s12325-025-03259-8","article-title":"Matching-adjusted indirect comparison of sotorasib versus adagrasib in previously treated advanced\/metastatic non-small cell lung cancer harboring kras g12c mutation","volume":"42","author":"Chopra","year":"2025","journal-title":"Adv. Ther."},{"issue":"10378","key":"10.1016\/j.ctarc.2026.101227_bib0017","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2026.101227_bib0018","first-page":"196","article-title":"Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with G12C mutation","author":"Waterhouse","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101227_bib0019","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.8518","article-title":"S1900E: A phase II study examining impact of co-mutations on sotorasib for previously treated stage IV\/recurrent KRAS G12C mutated (MUT) non-squamous (Non-sq) non-small cell lung cancer (NSCLC)(ECOG-ACRIN led Lung-MAP Sub-study)","author":"Padda","year":"2025","journal-title":"Am. Soc. Clin. Oncol."}],"updated-by":[{"DOI":"10.1016\/j.ctarc.2026.101240","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000}},{"DOI":"10.1016\/j.ctarc.2026.101240","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000}}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T21:19:45Z","timestamp":1783199985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":19,"alternative-id":["S2468294226001383"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101227","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101227"}}